Literature DB >> 17010524

The LKB1 tumor suppressor kinase in human disease.

Pekka Katajisto1, Tea Vallenius, Kari Vaahtomeri, Niklas Ekman, Lina Udd, Marianne Tiainen, Tomi P Mäkelä.   

Abstract

Inactivating germline mutations in the LKB1 gene underlie Peutz-Jeghers syndrome characterized by hamartomatous polyps and an elevated risk for cancer. Recent studies suggest the involvement of LKB1 also in more common human disorders including diabetes and in a significant fraction of lung adenocarcinomas. These observations have increased the interest towards signaling pathways of this tumor suppressor kinase. The recent breakthroughs in understanding the molecular functions of the LKB1 indicate its contribution as a regulator of cell polarity, energy metabolism and cell proliferation. Here we review how the substrates and cellular functions of LKB1 may be linked to Peutz-Jeghers syndrome and other diseases, and discuss how some of the molecular changes associated with altered LKB1 signaling might be used in therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010524     DOI: 10.1016/j.bbcan.2006.08.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  52 in total

1.  Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity.

Authors:  Johanna I Partanen; Topi A Tervonen; Mikko Myllynen; Essi Lind; Misa Imai; Pekka Katajisto; Gerrit J P Dijkgraaf; Panu E Kovanen; Tomi P Mäkelä; Zena Werb; Juha Klefström
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-20       Impact factor: 11.205

2.  Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization.

Authors:  Johanna I Partanen; Anni I Nieminen; Tomi P Mäkelä; Juha Klefstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-31       Impact factor: 11.205

3.  Integrated network analysis platform for protein-protein interactions.

Authors:  Jianmin Wu; Tea Vallenius; Kristian Ovaska; Jukka Westermarck; Tomi P Mäkelä; Sampsa Hautaniemi
Journal:  Nat Methods       Date:  2008-12-14       Impact factor: 28.547

4.  Cellular polarity in aging: role of redox regulation and nutrition.

Authors:  Helena Soares; H Susana Marinho; Carla Real; Fernando Antunes
Journal:  Genes Nutr       Date:  2013-12-04       Impact factor: 5.523

5.  Immunohistological evidence for Wnt-signaling activation in Peutz-Jeghers polyposis.

Authors:  Walawee Chaiyapan; Surasak Sangkhathat; Samornmas Kanngurn; Monlika Phukaoloun; Piyawan Chiengkriwate; Sakda Patrapinyokul
Journal:  Pediatr Surg Int       Date:  2009-12-18       Impact factor: 1.827

6.  Endothelial cell-specific liver kinase B1 deletion causes endothelial dysfunction and hypertension in mice in vivo.

Authors:  Wencheng Zhang; Qilong Wang; Yue Wu; Cate Moriasi; Zhaoyu Liu; Xiaoyan Dai; Qiongxin Wang; Weimin Liu; Zu-Yi Yuan; Ming-Hui Zou
Journal:  Circulation       Date:  2014-03-17       Impact factor: 29.690

Review 7.  Mammalian TOR signaling to the AGC kinases.

Authors:  Bing Su; Estela Jacinto
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-10-10       Impact factor: 8.250

8.  Liver kinase B1 is required for thromboxane receptor-dependent nuclear factor-κB activation and inflammatory responses.

Authors:  Jinlong He; Yanhong Zhou; Junjie Xing; Qilong Wang; Huaiping Zhu; Yi Zhu; Ming-Hui Zou
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-28       Impact factor: 8.311

9.  Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.

Authors:  Bin Zheng; Joseph H Jeong; John M Asara; Yuan-Ying Yuan; Scott R Granter; Lynda Chin; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-01-30       Impact factor: 17.970

10.  The CRTC1-NEDD9 signaling axis mediates lung cancer progression caused by LKB1 loss.

Authors:  Yan Feng; Ye Wang; Zuoyun Wang; Zhaoyuan Fang; Fei Li; Yijun Gao; Hongyan Liu; Tian Xiao; Fuming Li; Yang Zhou; Qiwei Zhai; Xiaolong Liu; Yihua Sun; Nabeel Bardeesy; Kwok-kin Wong; Haiquan Chen; Zhi-qi Xiong; Hongbin Ji
Journal:  Cancer Res       Date:  2012-10-16       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.